Translational Research

The Laboratory of Translational Research, led by Dr. Joel Moss, focuses on clinical and translational areas of investigation.

On This Page
Joel Moss

Clinical Trials and Studies

Study of the Disease Process of Lymphangioleiomyomatosis

Recruiting
All Ages
All Genders
Not Accepting Healthy Volunteers
Have you been diagnosed with LAM? This study is trying to understand the genes and proteins that are responsible for causing lung damage in patients with LAM. To participate in this study, you must be between 16 and 99 years old and diagnosed with LAM. This study is located in Bethesda, Maryland.

Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis

Recruiting
Adult, Older Adult
Female
Not Accepting Healthy Volunteers
Are you an adult female who has been diagnosed with LAM? This study is examining which delivery method of albuterol—inhaled or nebulizer—is better at improving lung function in adult women who have LAM. This study is located in Bethesda, Maryland.

Role of Genetic Factors in the Development of Lung Disease

Recruiting
All Ages
All Genders
Accepting Healthy Volunteers
Do you or your child have a lung disease? This study will investigate the genes involved in the breathing process and in the development of lung diseases such as asthma or sarcoidosis to improve understanding of the role they play. To participate in this study, you or your child must be between 2 and 90 years old. This study is located in Bethesda, Maryland, at the NIH Clinical Center.

Cutaneous Tumorigenesis in Patients with Tuberous Sclerosis

Recruiting
Adult, Older Adult
All Genders
Not Accepting Healthy Volunteers
Do you have tuberous sclerosis and want to help researchers better understand the disease? This study is investigating what causes multiple skin tumors to develop in people with tuberous sclerosis. To participate in the study, you must be at least 18 years old. This study is located at the NIH Clinical Center in Bethesda, Maryland.

Discovery of Sirolimus Sensitive Biomarkers in Blood

Recruiting
Adult, Older Adult
Female
Not Accepting Healthy Volunteers
Do you have LAM and would be willing to help research? This study aims to identify the right dose of sirolimus to treat people who have LAM. To participate in this study, you must be female, between 18 and 90 years old, and diagnosed with LAM. This study is located in Bethesda, Maryland.

Featured Publications

Effect of beta-agonists on LAM progression and treatment.

Authors: Le K, Steagall WK, Stylianou M, Pacheco-Rodriguez G, Darling TN, Vaughan M, Moss J.
Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):E944-E953
Read Publication

Use of CT Imaging to Quantify Progression and Response to Treatment in Lymphangioleiomyomatosis.

Authors: Gopalakrishnan V, Yao J, Steagall WK, Avila NA, Taveira-DaSilva AM, Stylianou M, Chen MY, Moss J.
Chest. 2019 May 01;155(5):962-971
Read Publication

Rates of change in FEV1 and DLCO as potential indicators for mTOR inhibitor therapy in premenopausal lymphangioleiomyomatosis patients.

Authors: Taveira-DaSilva AM, Julien-Williams P, Jones AM, Stylianou M, Moss J.
Eur Respir J. 2018 Apr 19;51(4):1702258
Read Publication

PARP1 inhibition alleviates injury in ARH3-deficient mice and human cells.

Authors: Mashimo M, Bu X, Aoyama K, Kato J, Ishiwata-Endo H, Stevens LA, Kasamatsu A, Wolfe LA, Toro C, Adams D, Markello T, Gahl WA, Moss J.
JCI Insight. 2019 Feb 21;4(4):e124519
Read Publication

Role of a TRIM72 ADP-ribosylation cycle in myocardial injury and membrane repair.

Authors: Ishiwata-Endo H, Kato J, Tonouchi A, Chung YW, Sun J, Stevens LA, Zhu J, Aponte AM, Springer DA, San H, Takeda K, Yu ZX, Hoffmann V, Murphy E, Moss J
JCI Insight 2018 Nov 15;3(22):
Read Publication
View More Publications

Meet the Team

Joel Moss

Joel Moss, M.D., Ph.D.

Senior Investigator

Joel Moss graduated summa cum laude from Brandeis University in 1966 with a B.A. in chemistry and earned his M.D. and Ph.D. degrees from New York University School of Medicine in 1972. Following internship and residency at Johns Hopkins Hospital, Dr. Moss joined the NHLBI in 1974 as a research associate and pulmonary fellow. Since 2007, he has been head of the Translational Research Section and of the Lymphangioleiomyomatosis (LAM) Research Program. Dr. Moss has received multiple awards, including LAM Foundation Award (1999 and 2010), and the New York University Alumni Achievement Award in Basic Science in 2009. Dr. Moss is an honorary member of the Peruvian Thoracic Society and received the Chiba (Japan) Medical Society Award. He is also a member of American Society for Clinical Investigation for which he was a Councillor and Vice-President. In 2009, Dr. Moss was elected to the Johns Hopkins University Society of Scholars. He is a Fellow of the American College of Chest Physicians. Dr. Moss has authored or coauthored more than 630 papers, edited and co-authored several books and is a co-inventor of several patents. Dr. Moss has been an editor of the Journal of Biological Chemistry and the Journal of Clinical Investigation. He is currently an Editor of the American Journal of Respiratory Cell and Molecular Biology and is a designated Associate Editor of CHEST through 2015.

Load more members